MIXED AMPHETAMINE SALTS MANUAL

In this report, we present the case of an adult female patient who showed symptoms consistent with DDD and responded well to treatment with mixed amphetamine salts.Ī 35-year-old woman seen by her primary care physician (PCP) for medication management presented to the psychiatric clinic to establish care. DDD is a disorder with a scant evidence base regarding effective interventions, and the diagnosis currently lacks any medication interventions approved by the United States Food and Drug Administration (FDA). The DSM-5 criteria for diagnosing DDD are summarized in Table 1. For the sake of brevity, when referencing either diagnosis, the abbreviation DDD will be used in this report. This diagnosis was formerly termed depersonalization disorder under DSM-4. When symptoms of depersonalization and/or derealization become recurrent or persistent, a person might be diagnosed with depersonalization/derealization disorder (DDD). Depersonalization and derealization symptoms can be triggered by seizures, migraines, head injury, and illicit drug use. These symptoms might be transient and appear to occur most commonly among adolescents and young adults. Another study found that 46 percent of college students had at least one episode of depersonalization in the past year.

MIXED AMPHETAMINE SALTS MANUAL

The Diagnostic and Statistical Manual of Mental Disorders, fifth edition ( DSM-5) defines depersonalization as “experiences of unreality, detachment, or being an outside observer with respect to one’s thoughts, feelings, sensations, body, or actions (e.g., perceptual alterations, distorted sense of time, unreal or absent self, emotional and/or physical numbing).” Derealization is defined as encompassing “experiences of unreality or detachment with respect to surroundings (e.g., individuals or objects are experienced as unreal, dreamlike, foggy, lifeless, or visually distorted).” 1 One survey found a one-year prevalence of 19 percent for depersonalization symptoms and 14 percent for derealization symptoms. KEYWORDS: Dissociative disorders, depersonalization, derealization, psychostimulantsĭissociative symptoms are common in the general population and can include experiences of depersonalization and derealization. Given the lack of evidence-based interventions for patients with DDD, additional research into the potential benefit of using psychostimulants might be warranted. We also reviewed the limited research examining the efficacy of lamotrigine, benzodiazepines, antidepressants, naltrexone, and antipsychotics in DDD. Her DDD symptoms notably reduced after treatment with mixed amphetamine salts. Here, we reported a case of an adult female whose presentation was consistent with DDD. This is a diagnosis with little evidence available regarding effective interventions, and there are currently no pharmacological treatments for DDD approved by the United States Food and Drug Administration (FDA). Recurrent, persistent symptoms can result in a diagnosis of depersonalization/derealization disorder (DDD). Weber is with Intermountain Healthcare in Logan, Utah.įUNDING: No funding was provided for this study.ĭISCLOSURES: The author has no conflicts of interest relevant to the content of this article.ĪBSTRACT: Depersonalization and derealization symptoms are common and often transient.

Mixed amphetamine salts